Sirtris Pharmaceuticals Scientific Advisory Board Co-Chairs Publish First In-Vivo Data Showing SIRT1 Enzyme Can Suppress Tumor Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced that a research team led by the company’s two Scientific Advisory Board co-chairs has demonstrated that overexpression of the SIRT1 enzyme can suppress tumor formation and growth in a preclinical mouse model of colon cancer, providing the first in-vivo data that SIRT1 can suppress tumor cell development. The paper, titled SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth, appears in today’s issue of the scientific journal PLoS One.